PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer

BACKGROUND: Pappalysin 2 (PAPPA2) mutation, occurring most frequently in skin cutaneous melanoma (SKCM) and non‐small cell lung cancer (NSCLC), is found to be related to anti‐tumour immune response. However, the association between PAPPA2 and the efficacy of immune checkpoint inhibitors (ICIs) thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Yiting, Zhao, Lele, Duan, Jianchun, Bai, Hua, Chen, Dongsheng, Li, Si, Yu, Yangyang, Xiao, Mingzhe, Zhang, Qin, Duan, Qianqian, Sun, Tingting, Qi, Chuang, Wang, Jie, Wang, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436912/
https://www.ncbi.nlm.nih.gov/pubmed/35811392
http://dx.doi.org/10.1111/cpr.13283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436912/
https://www.ncbi.nlm.nih.gov/pubmed/35811392
http://dx.doi.org/10.1111/cpr.13283

Ejemplares similares